1. Introduction {#sec1}
===============

Alzheimer\'s disease (AD, MIM 104300) is a major cause of disability in the elderly population. It is the most common form of dementia, affecting 1 in 8 individuals older than 60 years of age \[[@B1]\]. Most AD cases are late in onset and are probably influenced by both genetic and environmental factors. Clinically, AD generally begins with subtle short-term memory problems and then progresses to difficulties in memory, language, and orientation. In the late stage of AD, ventricular enlargement and shrinkage of the brain may be observed by magnetic resonance imaging. Some characteristic changes in the AD brain include neuronal loss in selected regions; intracellular neurofibrillary tangles in the neurons of the cerebral cortex and hippocampus; and neuritic plaques containing amyloids that may be further surrounded by dystrophic neurites, reactive astrocytes, and microglia \[[@B1]\].

Alzheimer Disease International estimates that there are currently 30 million cases of dementia in the world, with 4.6 million new cases occurring annually \[[@B2]\]. Statistics is much more ambiguous in the developing world, where few studies have examined the prevalence of dementia and where estimates vary widely. Evidence on the prevalence of AD is abundant in Europe and North America, patchy in South and Southeast Asia, and very limited in Africa, the Middle East, Russia, Eastern Europe, and Latin America \[[@B3]\].

Historically, the ancient Egyptians had words for the skull, brain, vertebrae, spinal fluid, and meninges and had described unconsciousness, quadriparesis, hemiparesis, and dementia \[[@B4]\]. Egypt has been the interest of many conquerors since the times of the ancient Pharaohs until the Arab-Israeli conflict, including the Osmania Empire, the French campaign, and British domination. Consequently, much intermarriage has occurred in Egypt, which could be reinforcing the heterogeneity, pleiotropy, and variable expressivity of hereditary disorders \[[@B5]\]. AD, in Egypt, has been reported as the most common form of dementia, accounting for 51.2% of all hereditary cases. Vascular dementia accounts for 28.7% of hereditary cases, general medical conditions such as Parkinsonism or Lewy body dementia for 12.8%, and multiple etiologies for 7.3% \[[@B4]\]. El Tallawy et al. \[[@B6]\] have reported that the prevalence of dementia in Egypt is 2.26% among those ≥50 years, 4.45% among those ≥60 years, 9.28% among those ≥70 years, and 18.48% among those ≥80 years. The Middle East is expected to face an increasing burden of AD as the population naturally ages.

Although a polymorphism in the apolipoprotein E (*ApoE*) gene has been found to be associated with familial AD, it might not provide a sensitivity or high-enough specificity to be used alone as a diagnostic test for the disease \[[@B7]\].

Much attention has been focused on the association between the rs1801133 single nucleotide polymorphism (SNP) in the methylenetetrahydrofolate reductase (*MTHFR*, MIM 607093) gene and AD. Genetic variations in this candidate gene may increase homocysteine levels or decrease levels of vitamin B12 \[[@B8], [@B9]\]. The MTHFR enzyme regulates homocysteine concentrations in humans and has been implicated in the pathogenesis of cardiovascular disease \[[@B10]\], congenital abnormalities \[[@B11]\], cancer \[[@B12]\], and psychiatric disorders \[[@B13]\].

Several *MTHFR* polymorphisms can cause severe homocystinuria or moderate or mild hyperhomocysteinemia. The most frequent rs1801133 SNP (Ala\>Val) in the *MTHFR*gene renders the MTHFR enzyme thermolabile and is linked to moderate hyperhomocysteinaemia \[[@B14]\]. Hyperhomocysteinaemia elevates the risk of mild cognitive impairment and dementia of the Alzheimer\'s type \[[@B15]\]. However, some studies have reported that an increase in plasma homocysteine may be an independent risk factor for the development of AD \[[@B16]\].

B12 deficiency (\<150 pmol/L) is associated with AD. Even the subclinical low normal range of B12 levels (\<250 pmol/L) is associated with AD, vascular dementia, and Parkinson\'s disease \[[@B9]\]. An association between AD and a low concentration of serum vitamin B12 has been described \[[@B9]\]. Additional data suggest that high intake of vitamin B12 is related to a low risk of AD. It has been reported that B vitamins may efficiently decrease the plasma level of the amyloid A*β*40 and thus have a role in preventing AD \[[@B17]\]. However, no association has been found between vitamin B12 intake and the risk of developing AD \[[@B18]\].

Cholesterol is another factor that may have direct implications for AD. It has been shown that animals fed a diet supplemented with 2% cholesterol have increased A*β* in the brain cortex and hippocampus. Furthermore, impaired brain cholesterol dynamics have been described as a potential cause of AD \[[@B19]\].

Despite the weight of genetic information on AD, only a few reports provide evidence on genetic-biochemical interactions that affect the risk of AD. Most of these reports are from Western countries. Our hypothesis is that the frequency of the T allele and of the T/T genotype of the rs1801133 SNP will be highly compared to the C allele and the C/C genotype or will be increasingly associated with the severe form of AD among Egyptians.

The aim of this study was to determine the genotype and allele frequencies of the rs1801133 SNP and to evaluate the influence of genotype on risk and severity of disease in Egyptian patients with AD. The study also sought to determine any associations between AD and either clinical characteristics or homocysteine, vitamin B12, and cholesterol levels in these patients.

2. Subjects and Methods {#sec2}
=======================

2.1. Population {#sec2.1}
---------------

The study was conducted among 75 elderly Egyptians (43 patients with AD plus 32 nondemented controls). All patients over the age of 59 years who were in the database at the Memory Disorder and Old Age Psychiatry Clinic, Psychiatry Department, Ain Shams University, Cairo, Egypt, over a six-month period were considered for inclusion in the study.

The National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer\'s Disease and Related Disorders Association (NINCDS-ADRDA) criteria were used to diagnose possible and probable AD. ICD-10 was among the clinical diagnostic criteria employed in this study. Mean cognitive test scores for AD patients were 12.3 ± 6.6 on the mini-mental state examination (MMSE), 31.8 ± 10.9 on the activities of daily living (ADL) index, and 12.1 ± 7.3 on the blessed dementia scale (BDS). Patients were examined for the presence of some of the vascular diseases common in Egyptians, such as diabetes mellitus type 2 and hypertension, and for the effects of anti-inflammatory drugs. The severity of AD was categorized as mild, moderate, or severe based on the stages of the clinical dementia rating (CDR).

AD cases were considered familial if dementia was documented in at least two first-degree relatives within two generations. If a reliable family history was not available, cases were termed sporadic. Cases were defined as early onset if age of onset was \<65 years with AD and as late onset if age of onset was \>65 years. Suspected cases of AD or other types of dementia were further examined by senior physicians through laboratory tests, clinical features, and neuropsychological tests.

Of 55 patients with AD, 43 cases (29 women and 14 men) were analyzed. Twelve patients (21.8%) refused to be clinically investigated or could not be located for followup. Twelve (27.9%) of the 43 patients had early-onset AD, and 31 (72.1%) had late-onset AD. The ages of the patients were 60--64 years (27.9%), 65--69 years (27.9%), 70--79 years (23.2%), and ≥80 years (21.0%).

We also examined a sample of 32 age-matched nondemented Egyptians (22 women and 10 men) who were recruited as controls from the local community where they were living unassisted. All controls were carefully assessed using a rigorous clinical history and CT scans and standard neuropsychological examinations to exclude any neurological disorders. Each member of the control group had an MMSE score ≥24, indicating that they were cognitively normal. The ages of the non-demented controls were 60--64 years (28.1%), 65--69 years (28.1%), 70--79 years (25%), and ≥80 years (18.8%).

This study was approved by the local Bioethics Committee. Patients or their caregivers provided written informed consent.

2.2. DNA Isolation {#sec2.2}
------------------

Genomic DNA was extracted from peripheral blood (0.2 mL) using the QIAamp DNA Blood kit (Qiagen Gm6H, Hilden, Germany). In some cases, DNA was prepared *in situ* by gently scraping the buccal mucosa for 30 s using a cytobrush \[[@B20]\]. The cells obtained were treated directly with diluted NaOH solution, heated, and neutralized with Tris-Cl, pH 8.0. A 2.5 *μ*L volume of buccal cells typically sufficed for amplification by polymerase chain reaction (PCR).

2.3. Genotyping of the rs1801133 Locus {#sec2.3}
--------------------------------------

Previously reported primers for the rs1801133 SNP---the forward primer 5′-TGA AGG AGA AGG TGT CTG CGG GA-3′ and the reverse primer 5′-AGG ACG GTG CGT GAG AGT G-3′ \[[@B14]\]---were used to amplify the 198-bp target region within the *MTHFR* gene. We performed 35 rounds of polymerase chain reaction (PCR) on thermal cycler Engine Dyad (Bio-Rad Laboratories Inc., USA) with annealing at 58°C for 30 s followed by final extension of 7 min. The PCR product was incubated with two units of the *Hinf*I enzyme at 37°C for 16 h (Fermentas GmbH, Germany). The digestion product was separated on a 3% MetaPhor agarose gel (BMA, Rockland, ME, USA). The product was then identified by ethidium bromide staining and was photographed using a gel-documentation system (G-Box, SynGene, Frederick, MD, USA). Positive controls for wild and variant genotypes were compared with the study samples ([Figure 1](#fig1){ref-type="fig"}). A positive control was used for each polymorphism. The genotypes of all samples were reassessed twice to confirm the results and ensure reproducibility. Some suspected genotypes were validated by purifying the PCR products using automated Agencourt AMPure XP kit (Beckman Coulter, Canada) and genotyping using Genetic Analyzer 3500 (ABI, Life Technologies, USA).

2.4. Biochemical Methods {#sec2.4}
------------------------

Fasting homocysteine and vitamin B12 levels were assessed in all AD cases and controls. Homocysteine levels in blood plasma were measured with a fluorescence polarization assay (Abbott IMX Homocysteine Assay), and plasma vitamin B12 levels were measured by immunoassay. Reference ranges were 4--12 *μ*mol/L for homocysteine and 157--1059 pg/mL for vitamin B12. Total lipids were measured using Roche Cobas Integra 400 Plus---Chemistry Analyzer (Diamond Diagnostics, MA, USA).

2.5. Data Analysis {#sec2.5}
------------------

Possible associations between genotypes and the clinical severity of disease were analyzed using the Mantel-Haenszel *χ*^2^ test for linear association (SPSS ver. 20.0, SPSS Inc., Chicago, IL USA). The distribution of the control genotypes was checked for the Hardy-Weinberg equilibrium using the *χ*^2^ test (<http://www.oege.org/software/hwe-mr-calc.shtml>).

The Student\'s *t*-test, *χ*^2^ test, and *F*-test were used to compare continuous and categorical variables. Multivariate logistic regression analysis was performed to assess the contributions of *MTHFR* 677C\>T alleles and other independent risk factors to the study outcomes. A probability \<0.05 was considered statistically significant. The odds ratio (OR) and relative risk of the 677T allele at a 95% confidence interval (CI) were also calculated using MedCalc for Windows, version 12.3.0.0 (MedCalc software, Mariakerke, Belgium).

We used G\*Power software (Germany, version 3.1.5, <http://www.psycho.uni-duesseldorf.de/abteilungen/aap/gpower3/download-and-register/>) to perform *priori* power analysis to estimate sufficient sample sizes to achieve adequate power for z-testing of two independent proportions. *Priori* sample size estimations were performed using known information on the common allele frequencies in AD and demented healthy controls, a criterion probability of *α* = 0.05, and a power sensitivity of 80%.

3. Results {#sec3}
==========

The genotype distribution and allele frequencies of the rs1801133 SNP are shown in [Table 1](#tab1){ref-type="table"}. The genotype frequencies satisfied the Hardy-Weinberg equilibrium in the controls, and the difference between the expected and observed values for the control genotypes was not significant (*χ*^2^ = 0.24; *P* = 0.63).

The 677C/C genotype was more frequent in controls (62.5%) than in AD cases (41.9%). Although there were no significant differences in the frequencies of the *MTHFR* alleles or genotypes between AD cases and controls (*χ*^2^ = 3.99; *P* = 0.14), the frequency of the 677T/T genotype was three times higher for AD cases than for controls (18.6% versus 6.3%). Also, the frequency of the heterozygous C/T genotype was higher for AD cases (40%) than for controls (31%) ([Table 1](#tab1){ref-type="table"}). There was no significance difference between early-onset AD (*n* = 12) and late-onset AD (*n* = 31) regarding genotype distributions or allele frequencies (*P* = 0.37 or *P* = 0.28, resp.) ([Table 1](#tab1){ref-type="table"}).

As for allele frequency, the T allele was significantly overrepresented in the AD group when compared with the control group (38% versus 22%). The C allele was more frequent than the T allele in both AD cases and controls (62% versus 38% and 78% versus 22%, resp.) ([Table 1](#tab1){ref-type="table"}). The OR of the mutant T allele outcome was 2.22 (95% CI, 1.1--4.6; *Z* = 2.13; *P* = 0.03). Consequently, the relative risk of the mutant T allele outcome was 1.75 (95% CI, 1.0--3.0; *Z* = 2.06; *P* = 0.04).

As shown in [Table 2](#tab2){ref-type="table"}, the 677C\>T polymorphism was nearly significantly associated with the severity of AD (*χ*^2^ = 7.2; *P* = 0.05). Of the 43 AD cases, 26 (60.5%) were mild, 6 (14.0%) were moderate, and 11 (25.6%) were severe. Severe AD was more frequent in patients with the 677T/T genotype (11.6%) than in patients with the C/C (9.4%) or C/T (4.7%) genotypes.

In terms of clinical characteristics ([Table 3](#tab3){ref-type="table"}), the majority of AD cases were sporadic (95.3%) with a late age of onset (58%). Of the 43 patients with AD, 19% were illiterate, 72% had \<8 years of education, and 9% had a higher level of education. About 40% of the women and 40% of the men were factory workers, and 18% of the women and 32% of the men were farmers. There were no significant effects of diabetes type 2, hypertension, anti-inflammatory drugs, or other psychiatric disorders on the incidence of AD (*P* \> 0.05).

As shown in [Table 3](#tab3){ref-type="table"}, the mean level of total homocysteine in plasma was significantly higher in AD cases (18.4 ± 6.3 *μ*mol/L) than in controls (13.0 ± 3.8 *μ*mol/L) (*P* \< 0.0001). Moreover, plasma homocysteine was significantly higher in AD cases with the T/T genotype (*P* \< 0.05) than in those with the C/T or C/C genotype. The mean level of vitamin B12 was significantly lower in AD patients (310.1 ± 120.2 pg/mL) than in controls (400.2 ± 238.0 pg/mL) (*P* = 0.0005). According to results of the lipid assessment, the mean level of total cholesterol in the AD group was slightly higher than the reference range, but this difference was not significant (*P* \> 0.05) ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

Although environmental factors clearly influence the onset, progression, and severity of AD, family studies indicate that genetic variation also influences susceptibility. As shown in [Table 4](#tab4){ref-type="table"}, the frequencies of the T allele and of the homozygous mutant genotype 677T/T in our Egyptian population (38.4% and 18.6%, resp.) are midway between the frequencies in Caucasians, who have the lowest frequencies \[[@B21]\], and East Asians, who have the highest frequencies \[[@B31]\].

Whether the 677C\>T polymorphism is a risk factor for AD has been addressed in several populations, as shown in [Table 4](#tab4){ref-type="table"}. However, only a few studies have reported a positive association \[[@B22], [@B24], [@B33]\]. There are cross-population differences in the frequency of the 677T/T genotype in patients with AD, ranging from 8% in Caucasian-Polish populations to 44% in East Asian (Chinese) \[[@B31]\]. In addition, the 677T allele frequency ranges from 27--30% in Polish populations \[[@B21]\] to 62% in Korean populations \[[@B33]\].

A meta-analysis has recently shown that the *MTHFR* 677C\>T polymorphism can cause AD susceptibility in East Asians but not in Caucasians \[[@B34]\]. This supports the results of our study, which found no significant association between the 677C\>T polymorphism and AD. Although a positive association has been found between *MTHFR* genotypes and AD in East Asians \[[@B31], [@B34]\], the samples that were tested were smaller for East Asians than for Caucasians. Moreover, the control groups in some studies were non-demented individuals or hospital-based controls, which could have greatly affected the results.

Sporadic forms of AD generally affect patients later in life, with onset usually occurring between the ages of 60 and 70. Although sporadic cases made up the majority of AD cases in our study, 4.7% of the cases were genetically linked familial forms of AD. Of the sporadic cases, most were late-onset cases with a complex etiology due to interactions between environmental conditions and genetic features of the individual. A major susceptibility gene, *ApoE*, is commonly associated with sporadic late-onset AD \[[@B35]\]. Our results with the *MTHFR* gene are in agreement with other studies suggesting that polymorphisms in other genes, such as genes for the amyloid precursor protein (APP, MIM 104760), presenilin 1 (PSEN1, MIM 104311), and presenilin 2 (PSEN2, MIM 600759), account for less than 5% of AD cases \[[@B35], [@B36]\].

Several case-control studies have found AD patients to be deficient in certain micronutrients such as folate and vitamin B12 but to have elevated levels of the sulfur-based amino acid homocysteine. The essential inquiry remains whether the observed high homocysteine levels are a cause or a consequence of AD. Normal homocysteine levels range from 4 to 12.3 *μ*mol/L, and these levels increase with age. High levels of homocysteine are common in the elderly demented population, and some studies report that this is probably secondary factors in most cases \[[@B15]\].

Our study clearly shows that the level of homocysteine in plasma was significantly higher (*P* \< 0.0001) in AD cases than in controls. As expected, this suggests that hyperhomocysteinaemia is an independent risk factor for the development of AD, which is consistent with most studies \[[@B16], [@B18]\]. Moreover, we found that our AD cases had significantly lower levels of vitamin B12 (*P* = 0.0005), as similarly shown by Wang et al. \[[@B24]\]. Plasma homocysteine has been reported as a sensitive marker for deficiencies of both vitamin B12 and folates in tissues of the psychogeriatric population.

Moore et al. \[[@B9]\] showed that low serum levels of vitamin B12 are associated with neurodegenerative disease and cognitive impairment and that vitamin B12 therapy does not improve cognition in patients without preexisting deficiency. This result was not confirmed by Coppedè et al. \[[@B38]\], who reported that differences in serum vitamin B12 levels between AD cases (*n* = 378) and non-demented controls (*n* = 308) did not reach statistical significance.

Several studies have dealt with the effect of cathepsin B, a candidate protease involved in the conversion of *β*-amyloid precursor protein into the amyloid plaques, on AD. Sundelöf et al. \[[@B39]\] have reported that cathepsin B in plasma was higher in persons with AD compared to healthy controls (*P* = 0.05). Consequently, these outcomes have demonstrated pharmacogenetic differences in the effects of inhibitors of cathepsin B to improve memory deficits. Therefore, inhibitors of cathepsin B or even deletion of the cathepsin B gene may be an effective drug target for improving memory deficits in most AD patients \[[@B40]\].

Our results identified a trend in which the prevalence of AD decreased with more years of education. Among the patients with AD, 19% were illiterate, 72% had \<8 years of education, and 9% had a higher level of education. These results agree with those of a recent Egyptian study \[[@B6]\] reporting a significantly higher prevalence of dementia among illiterate study participants (6.4%; *P* \< 0.0001) than among educated ones (0.6%). However, in addition to education, other lifestyle patterns such as diet, exercise, social interaction, worship attendance, alcohol consumption, and smoking may protect against clinical manifestation of AD.

The estimated sample size needed to reveal differences in allele frequencies between the AD and control groups (aiming at a power of 80%) was 128 in each group (a total of 256 participants). Based on differences in the allele frequencies of the 677C\>T polymorphism between our 43 AD cases and 32 controls, our post *hoc* statistical analysis revealed a power of 33%. However, recruiting more elderly participants within a reasonable time frame from a single center would have been difficult. Hence, replication of our results through larger, multicenter genetic association studies will be important.

The present study had several additional limitations. First, because certain regions of the world are only beginning to recognize the magnitude of the AD burden, sufficient data may be lacking for a realistic understanding of the genetic drift of the mutant 677T allele in patients with AD. Second, a lack of healthcare resources and financial support in Egypt, as in most developing countries, affects the ability to study all possible clinical factors that could have affected the severity of the disease. Also, the patients with AD may have had other clinical risk factors that are associated with mutations or polymorphisms in the *MTHFR* gene or with AD, such as hypertension, coronary artery disease, stroke, and cancer. Third, we initially wanted to test folate levels and their association with AD, but we could not track the majority of AD patients for this assay and so excluded it from our study.

5. Conclusions {#sec5}
==============

This is the first study, to our knowledge, to report some association between the *MTHFR* 677C\>T polymorphism and AD in the Egyptian population. We found that the *MTHFR* T/T genotype and the T allele were significantly associated with severity of AD and that their frequencies in the Egyptian population are midway between those found in different ethnic populations. However, the high prevalence of benign polymorphisms in the general population and our limited sample size (43 cases and 32 controls) may help to explain why no statistically significant associations were found. In addition, the concentration of plasma homocysteine was increased in AD cases, and this may be associated with the *MTHFR* 677T/T genotype.

The literature on the relationship between the *MTHFR* 677C\>T polymorphism and AD in the Middle East is limited. Larger trials with larger patient populations are needed to reach definite conclusions as to whether this polymorphism is a noteworthy risk factor for AD. It is unlikely that the *MTHFR* 677C\>T polymorphism is sufficient to cause a complex array of symptoms. The identification of new susceptibility genes has opened new avenues for exploring the underlying disease mechanisms for AD.
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![Electrophoretic gel pattern of the 677C\>T polymorphism in the *MTHFR* gene. The C allele gives the uncut 198-bp PCR product. The T allele, having a *Hinf*I restriction site, appears as a 175-bp product. The 23-bp fragment of the T allele is not shown on the gel. The C/T genotype is heterozygous.](DM35-05-524106.001){#fig1}

###### 

Genotype distribution and allele frequencies for the *MTHFR* rs1801133 single nucleotide polymorphism in Alzheimer\'s cases and controls.

  -------------------------------------------------------------------------------------------------------------------------
  Group      No. of patients   Genotype\   *χ* ^2^     *P* value   Allele frequency\                         
                               *n* (%)                             *n* (%)                                   
  ---------- ----------------- ----------- ----------- ----------- ------------------- --------- ----------- --------------
  EAD        12                7 (58.3)    3 (25.0)    2 (16.7)    2.00                0.37^a^   17 (0.71)   7 (0.29)

  LOAD       31                11 (35.5)   14 (45.2)   6 (19.4)    1.02                0.28^b^   36 (0.58)   26 (0.42)

  AD cases   43                7 (58.3)    17 (39.5)   8 (18.6)    3.99                0.14^c^   53 (0.62)   33 (0.38)^d^

  Controls   32                20 (62.5)   10 (31.2)   2 (6.3)                                   50 (0.78)   14 (0.22)
  -------------------------------------------------------------------------------------------------------------------------

Abbreviations. AD: Alzheimer\'s disease, EAD: early-onset AD, LOAD: late-onset AD.

^a^No significant difference in genotype distributions between EAD and LOAD cases (*P* \> 0.05).

^b^No significant difference in allele frequencies between EAD and LOAD cases (*P* \> 0.05).

^c^No significant difference in genotypes between AD cases and controls (*P* \> 0.05).

^d^Significant difference in the frequencies of the T alleles between AD cases and controls (OR = 2.22 (95% CI, 1.1--4.6; *P* = 0.03)).

###### 

Genotype distribution of the rs1801133 single nucleotide polymorphism and severity of Alzheimer\'s disease.

  ------------------------------------------------------------------------------------
  Severity of Alzheimer\'s disease^a^   Patients\   Genotype\               
                                         *n* (%)    *n* (%)                 
  ------------------------------------- ----------- ----------- ----------- ----------
  Mild                                  26 (60.5)   3 (7.0)     14 (32.6)   9 (20.9)

  Moderate                              6 (14.0)    1 (2.3)     1 (2.3)     4 (9.3)

  Severe                                11 (25.6)   4 (9.4)     2 (4.7)     5 (11.6)
  ------------------------------------------------------------------------------------

^a^The severity of Alzheimer\'s disease was evaluated using stages of the clinical dementia rating (CDR). In this rating, a null value is used for no dementia; 0.5 for questionable dementia; and 1, 2, and 3 for mild, moderate, and severe dementia, respectively.

###### 

Clinical characteristics and plasma levels of homocysteine, vitamin B12, and lipids in Alzheimer\'s cases and controls.

  ---------------------------------------------------------------------------------------
  Parameter                         AD cases           Controls        Reference values
  --------------------------------- ------------------ --------------- ------------------
  Number of patients                43                 32               

  Gender ratio (male : female)      1 : 2.1            1 : 2.2          

  Age range, years                  60--88             60--88           

  Mean age ± SD, years              69.2 ± 8.1         70.7 ± 8.8 y\    

  Late onset (\>65 y)^a^            25 (58.1%)         ---              

  Family history, (+)^a,b^          2 (4.7%)           0 (0%)           

  Educational level (\<8 y)^a^      39 (91%)           26 (81%)         

  Diabetes Mellitus, yes^a^         14 (32.6%)         7 (21.9%)        

  Hypertension, yes^a^              17 (39.5%)         18 (41.9%)       

  Anti-inflammatory drugs, yes^a^   5 (11.6%)          6 (18.8%)        

  Homocysteine^c^                   18.4 ± 6.3^d^      13.0 ± 3.8      4--12.3 *μ*mol/L

  Vitamin B12^c^                    310.1 ± 120.2^e^   400.2 ± 238.0   157--1059 pg/mL

  Total cholesterol^c^              210.5 ± 30.1^f^    205 ± 40.5      150--200 mg/dL

  LDL^c^                            133.5 ± 32.5^f^    130.4 ± 20.8    100--129 mg/dL

  HDL^c^                            57.7 ± 18.4^f^     55.3 ± 15.5     \>45 mg/dL

  Triglycerides^c^                  113.0 ± 60.0^f^    125.4 ± 65.3    60--150 mg/dL
  ---------------------------------------------------------------------------------------

Abbreviations. AD: Alzheimer\'s disease; SD: standard deviation.

^a^Number of patients, with percentages in parentheses.

^b^Family history was considered (+) if there was more than one case of Alzheimer\'s disease in the same family and (−) if the case was sporadic.

^c^Student\'s *t*-test. Values are mean ± SD.

^d^ *P* \< 0.0001, very highly significant difference.

^e^ *P* = 0.0005, highly significant difference.

^f^ *P* \> 0.05, no significant difference.

###### 

Distribution of *MTHFR* 677C\>T genotypes and their allelic frequencies in Alzheimer\'s cases and controls from different ethnic populations.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country (population)^a^\               No. of cases\       Distribution of rs1801133 SNP genotypes^b^   Frequency of T allele\                   
  \[Reference\]                          (no. of controls)                                                                                         
  -------------------------------------- ------------------- -------------------------------------------- ------------------------ --------------- -----------------------
  Poland (Caucasian) \[[@B21]\]          99 (100)            53.5 (55.0)                                  38.4 (38.0)              8.1 (7.0)       27.3^c^ (26.0)

  Iran (others) \[[@B22]\]               117 (125)           48.7 (67.2)                                  37.6 (26.4)              13.7 (6.4)      32.5^d^ (19.6)

  N. Ireland (Caucasian) \[[@B23]\]      83 (71)             71.1 (70.4)                                  24.1 (26.8)              4.8 (2.8)       33.7^d^ (16.2)

  China (East Asia) \[[@B24]\]           104 (100)           48.1 (60.8)                                  36.5 (36.2)              15.4 (3.0)      33.7^d^ (21.2)

  Brazil (others) \[[@B25]\]             30 (29)             36.7 (51.7)                                  56.7 (37.9)              6.6 (10.4)      35.0^d^ (29.7)

  *Egypt  (current study)*               *43  (32)*          *41.9  (62.5)*                               *39.5  (31.2)*           *18.6  (6.3)*   *38.4* ^c^ *  (21.9)*

  China (East Asia) \[[@B26]\]           105 (102)           37.1 (33.3)                                  42.9 (48.0)              20.0 (18.7)     41.4^c^ (42.6)

  United States (Caucasian) \[[@B27]\]   124 (97)            33.0 (38.0)                                  50.5 (59.9)              16.5 (11.1)     41.8^c^ (36.5)

  Japan (East Asian) \[[@B28]\]          194 (379)           33.0 (38.0)                                  50.5 (50.9)              16.5 (11.1)     41.8^c^ (36.5)

  Israel (others) \[[@B29]\]             49 (40)             24.5 (37.5)                                  63.3 (40.0)              12.2 (22.2)     45.7^c^ (42.5)

  Italy (Caucasian) \[[@B30]\]           231 (137)           27.7 (28.5)                                  52.0 (47.4)              20.3 (24.1)     46.3^c^ (47.8)

  China (East Asian) \[[@B31]\]          386 (375)           46.4 (24.0)                                  32.4 (45.9)              44.4 (30.1)     55.6^c^ (53.1)

  Sweden (Caucasian) \[[@B32]\]          204 (172)           48.0 (48.3)                                  44.1 (39.5)              7.9 (12.2)      59.8 (32.0)

  Korea (East Asian) \[[@B33]\]          86 (625)            12.8 (19.5)                                  50.0 (53.1)              37.2 (27.4)     62.2^c^ (53.9)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations. AD: Alzheimer\'s disease, SNP: single nucleotide polymorphism.

^a^Populations are arranged in ascending order of the frequency of the T alleles in Alzheimer\'s cases.

^b^Genotype distributions of AD cases, with distributions of controls in parentheses.

^c^The distribution of the *MTHFR* 677T allele does not differ between Alzheimer\'s cases and controls (*P* \> 0.05).

^d^The distribution of the *MTHFR* 677T allele is significantly different between Alzheimer\'s cases and controls (*P* \< 0.05).
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